drugset / Trial / NCT02680782
A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the safety, tolerability and pharmacokinetics of X4P-001 administered as 200 mg twice daily compared with 400 mg once daily. This study will also assess the pharmacodynamic effects of X4P-001 administered as 200 mg twice daily compared with 400 mg once daily on levels of circulating white blood cells (total and by cell type).
Timeline
- Start
- 2016-01-12
- Primary completion
- 2016-02-28
- Completion
- 2016-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mavorixafor | Small molecule | 200 mg | Oral |
| Subject | Mavorixafor | Small molecule | 400 mg | Oral |
Indications
No indication recorded.